Disease · HP_0100582

Comparisons in its trials20

Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.

1 to 20 of 20

Download this page as JSON

Comparison	Group 1, with the outcome	Group 2, with the outcome	Participants	Trial	Source
Benralizumab vs Placebo: Time to First Asthma Exacerbation (up to Week 24)	123 of 427	107 of 229	656	NCT03170271	Trial comparisons
Benralizumab vs Placebo: deaths from any cause	0 of 427	0 of 229	656	NCT03170271	Trial comparisons
Benralizumab vs Placebo: serious adverse events	23 of 427	25 of 229	656	NCT03170271	Trial comparisons
Dupilumab 300 mg vs Placebo: deaths from any cause	0 of 143	0 of 132	275	NCT02912468	Trial comparisons
Dupilumab 300 mg vs Placebo: serious adverse events	6 of 143	19 of 132	275	NCT02912468	Trial comparisons
Double Blind Benralizumab vs Double Blind Placebo: Percentage of Participants With Surgery and/or Use SCS for CRSwNP	26 of 139	30 of 135	274	NCT04157335	Trial comparisons
Double Blind Benralizumab vs Double Blind Placebo: Percentage of Participants With Surgery for CRSwNP	8 of 139	10 of 135	274	NCT04157335	Trial comparisons
Double Blind Benralizumab vs Double Blind Placebo: Percentage of Participants With SCS Use for CRSwNP	21 of 139	22 of 135	274	NCT04157335	Trial comparisons
Rimegepant vs Placebo: deaths from any cause	0 of 99	0 of 105	204	NCT05248997	Trial comparisons
Rimegepant vs Placebo: serious adverse events	0 of 99	0 of 105	204	NCT05248997	Trial comparisons
Mepolizumab 750 mg vs Placebo: deaths from any cause	0 of 53	0 of 52	105	NCT01362244	Trial comparisons
Mepolizumab 750 mg vs Placebo: serious adverse events	0 of 53	0 of 52	105	NCT01362244	Trial comparisons
Dupilumab 300 mg QW vs Placebo: deaths from any cause	0 of 30	0 of 30	60	NCT01920893	Trial comparisons
Dupilumab 300 mg QW vs Placebo: serious adverse events	2 of 30	4 of 30	60	NCT01920893	Trial comparisons
Xolair (Omalizumab) vs Xolair Placebo: deaths from any cause	0 of 13	0 of 14	27	NCT01066104	Trial comparisons
Xolair (Omalizumab) vs Xolair Placebo: serious adverse events	0 of 13	0 of 14	27	NCT01066104	Trial comparisons
ACT-774312 vs Placebo: deaths from any cause	0 of 7	0 of 3	10	NCT03688555	Trial comparisons
ACT-774312 vs Placebo: serious adverse events	0 of 7	0 of 3	10	NCT03688555	Trial comparisons
Dupilumab vs Placebo: deaths from any cause	0 of 3	0 of 2	5	NCT05545072	Trial comparisons
Dupilumab vs Placebo: serious adverse events	0 of 3	0 of 2	5	NCT05545072	Trial comparisons

diseases-2026-09-18-0.1.0

Sources 6

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ChEMBL, through Open TargetsCC BY-SA 3.0
ClinicalTrials.govNo license stated
NLM's MeSHNLM's terms
Open TargetsCC0 1.0
PubMedNLM's terms

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
ClinicalTrials.govnone stated
NLM's MeSHNLM's
Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
PubMedNLM's terms

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this list from software.

Twenty rows a page, as JSON. No key.

GET https://conductscience.org/api/diseases/v1/HP_0100582/comparisons

API reference For AI assistants